Cited by 1,322PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.

mTOR and cancer: insights into a complex relationship

Sabatini, David M.·2006·Nature Reviews Cancer

DOI 10.1038/nrc1974

Open this paper in CoChat — free account

Abstract

mTOR (mammalian target of rapamycin) has come a long way since its humble beginnings as a kinase of unknown function. As part of the mTORC1 and mTORC2 complexes mTOR has key roles in several pathways that are involved in human cancer, stimulating interest in mTOR inhibitors and placing it on the radar of the pharmaceutical industry. Here, I discuss the rationale for the use of drugs that target mTOR, the unexpectedly complex mechanism of action of existing mTOR inhibitors and the potential benefits of developing drugs that function through different mechanisms. The purpose is not to cover all aspects of mTOR history and signalling, but rather to foster discussion by presenting some occasionally provocative ideas.

Integrity signals

Registry

Crossref · 10.1038/nrc1974

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Self-citation
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery
Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051
Self-citation
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Self-citation
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Self-citation
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097
Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

Show all 94 references

Sorted by citations

Items 301–400 of 1,000

Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor
Zou, C., Smith, K. D., Zhu, Q.-S., Liu, J., McCutcheon, I. E., Slopis, J. M., Meric‐Bernstam, F., Peng, Z., Bornmann, W. G., Mills, G. B., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1008 · Cited by 88
mTORC2 targets AGC kinases through Sin1-dependent recruitment
Cameron, A. J. M., Linch, M. D., Saurin, A. T., Escribano, C., & Parker, P. J. (2011) · Biochemical Journal · doi:10.1042/bj20110678 · Cited by 85
Alteration of Cellular Behavior and Response to PI3K Pathway Inhibition by Culture in 3D Collagen Gels
Fallica, B., Maffei, J. S., Villa, S., Makin, G., & Zaman, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048024 · Cited by 84
Nutrient signals driving cell growth
Dechant, R. C., & Peter, M. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.09.009 · Cited by 84
Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway
Roediger, J., Hessenkemper, W., Bartsch, S., Manvelyan, M., Huettner, S. S., Liehr, T., Esmaeili, M., Foller, S., Petersen, I., Grimm, M., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-214 · Cited by 86
Genetically Distinct and Clinically Relevant Classification of Hepatocellular Carcinoma: Putative Therapeutic Targets
Katoh, H., Ojima, H., Kokubu, A., Saito, S., Kondo, T., Kosuge, T., Hosoda, F., Imoto, I., Inazawa, J., Hirohashi, S., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.038 · Cited by 85
E3 ligase RNF167 and deubiquitinase STAMBPL1 modulate mTOR and cancer progression
Wang, D., Xu, C., Yang, W., Chen, J., Ou, Y., Guan, Y., Guan, J., & Liu, Y. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.01.002 · Cited by 83
Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation
Gregory, E. N., Codeluppi, S., Gregory, J. A., Steinauer, J., & Svensson, C. I. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.067 · Cited by 84
Metabolic complications with the use of mTOR inhibitors for cancer therapy
Sivendran, S., Agarwal, N., Gartrell, B. A., Ying, J., Boucher, K. M., Choueiri, T. K., Sonpavde, G., Oh, W. K., & Galsky, M. D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.005 · Cited by 85
A Metabolism Toolbox for CAR T Therapy
Xu, X., Gnanaprakasam, J. R., Sherman, J. W., & Wang, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00322 · Cited by 82
Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex
Anderl, S., Freeland, M., Kwiatkowski, D. J., & Goto, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr393 · Cited by 81
From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer
Ilkow, C. S., Swift, S. L., Bell, J. C., & Diallo, J. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003836 · Cited by 81
Timosaponin AIII Is Preferentially Cytotoxic to Tumor Cells through Inhibition of mTOR and Induction of ER Stress
King, F. W., Fong, S., Griffin, C. A., Shoemaker, M., Staub, R., Zhang, Y., Cohen, I. V., & Shtivelman, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007283 · Cited by 83
The Birt-Hogg-Dube and Tuberous Sclerosis Complex Homologs Have Opposing Roles in Amino Acid Homeostasis in Schizosaccharomyces pombe
van Slegtenhorst, M., Khabibullin, D., Hartman, T. R., Nicolas, É., Kruger, W. D., & Henske, E. P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700857200 · Cited by 81
Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas
Schultz, L., Chaux, A., Albadine, R., Hicks, J. L., Kim, J., Marzo, A. M. D., Allaf, M. E., Carducci, M. A., Rodríguez, R., Hammers, H.-J., et al. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31822895e5 · Cited by 79
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44)
Huober, J., Fasching, P. A., Hanusch, C. A., Rezai, M., Eidtmann, H., Kittel, K., Hilfrich, J., Schwedler, K., Blohmer, J., Tesch, H., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.027 · Cited by 80
PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors
Wolin, E. M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.016 · Cited by 82
IQGAP1 regulates cell proliferation through a novel CDC42-mTOR pathway
Wang, J.-B., Sonn, R., Tekletsadik, Y. K., Samorodnitsky, D., & Osman, M. A. (2009) · Journal of Cell Science · doi:10.1242/jcs.044644 · Cited by 80
Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs
Paoloni, M. C., Mazcko, C. N., Fox, E., Fan, T. M., Lana, S. E., Kisseberth, W. C., Vail, D. M., Nuckolls, K., Osborne, T. S., Yalkowsy, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011013 · Cited by 80
mTOR Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis
Roy, D., Sin, S., Lucas, A., Venkataramanan, R., Wang, L., Eason, A. B., Chavakula, V., Hilton, I. B., Tamburro, K. M., Damania, B., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1851 · Cited by 80
Molecularly targeted therapies in cervical cancer. A systematic review
Zagouri, F., Sergentanis, T. Ν., Chrysikos, D., Filipits, M., & Bartsch, R. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.04.007 · Cited by 80
Hsp70 associates with Rictor and is required for mTORC2 formation and activity
Martin, J., Masri, J., Bernath, A., Nishimura, R. N., & Gera, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.086 · Cited by 79
SnapShot: Ras Signaling
Cully, M., & Downward, J. (2008) · Cell · doi:10.1016/j.cell.2008.06.020 · Cited by 80
Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma
Hansel, D. E., Platt, E., Orloff, M. S., Harwalker, J., Sethu, S., Hicks, J. L., Marzo, A. D., Steinle, R., Hsi, E. D., Theodorescu, D., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090872 · Cited by 79
Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility
Jhanwar-Uniyal (2009) · International Journal of Oncology · doi:10.3892/ijo_00000386 · Cited by 79
A Rictor-Myo1c Complex Participates in Dynamic Cortical Actin Events in 3T3-L1 Adipocytes
Hagan, G. N., Lin, Y., Magnuson, M. A., Avruch, J., & Czech, M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00867-07 · Cited by 76
Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes
Feldmeyer, N., Wabnitz, G. H., Leicht, S., Luckner‐Minden, C., Schiller, M. R., Franz, T., Conradi, R., Kropf, P., Müller, I., Ho, A. D., et al. (2012) · International Immunology · doi:10.1093/intimm/dxs004 · Cited by 81
Controlling cell growth and survival through regulated nutrient transporter expression
Edinger, A. L. (2007) · Biochemical Journal · doi:10.1042/bj20070490 · Cited by 77
Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer
Jin, N. Y., Jiang, T., Rosen, D. M., Nelkin, B. D., & Ball, D. W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0662 · Cited by 78
Hydrogen Peroxide Induces G2 Cell Cycle Arrest and Inhibits Cell Proliferation in Osteoblasts
Li, M., Zhao, L., Liu, J., Liu, A., Zeng, W., Luo, S.-Q., & Bai, X. (2009) · The Anatomical Record · doi:10.1002/ar.20925 · Cited by 76
Simian Virus 40 Small T Antigen Activates AMPK and Triggers Autophagy To Protect Cancer Cells from Nutrient Deprivation
Hindupur, S. K., & Rangarajan, A. (2009) · Journal of Virology · doi:10.1128/jvi.00603-09 · Cited by 78
Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells
Li, S., Oh, Y.-T., Yue, P., Khuri, F. R., & Sun, S.-Y. (2015) · Oncogene · doi:10.1038/onc.2015.123 · Cited by 76
Cordycepin Down-Regulates Multiple Drug Resistant (MDR)/HIF-1α through Regulating AMPK/mTORC1 Signaling in GBC-SD Gallbladder Cancer Cells
Wu, W., Hu, Z., Shang, M., Zhao, D.-J., Zhang, C.-W., Hong, D., & Huang, D. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150712778 · Cited by 75
Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy
Schultz, L., Albadine, R., Hicks, J. L., Jadallah, S., Marzo, A. M. D., Chen, Y., Neilsen, M. E., Gonzalgo, M. L., Sidransky, D., Schoenberg, M., et al. (2010) · Cancer · doi:10.1002/cncr.25502 · Cited by 75
CD9 induces cellular senescence and aggravates atherosclerotic plaque formation
Cho, J. H., Kim, E.-C., Son, Y., Lee, D.-W., Park, Y. S., Choi, J. H., Cho, K., Kwon, K., & Kim, J.-R. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0537-9 · Cited by 73
IL-2– and IL-15–induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes
Marzec, M., Liu, X., Kasprzycka, M., Witkiewicz, A. K., Raghunath, P. N., El-Salem, M., Robertson, E. S., Ødum, N., & Wasik, M. A. (2007) · Blood · doi:10.1182/blood-2007-06-095182 · Cited by 75
Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma
Tsuchiya, M., Parker, J. S., Kono, H., Matsuda, M., Fujii, H., & Rusyn, I. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-74 · Cited by 75
Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: A tale of two complexes
Jhanwar‐Uniyal, M., Gillick, J. L., Neil, J. A., Tobias, M. E., Thwing, Z. E., & Murali, R. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.09.004 · Cited by 77
Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro
Darb‐Esfahani, S., Faggad, A., Noske, A., Weichert, W., Buckendahl, A., Müller, B. M., Budczies, J., Roske, A.-E., Dietel, M., & Denkert, C. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0529-5 · Cited by 74
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
Huynh, H. T., Chow, P. K. H., Palanisamy, N., Salto‐Tellez, M., Goh, B. C., Lee, C. K., Anaji, S., Lee, H. S., Kalpana, R., Yu, K., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.02.022 · Cited by 74
Intermittent Bolus Feeding Has a Greater Stimulatory Effect on Protein Synthesis in Skeletal Muscle Than Continuous Feeding in Neonatal Pigs
Gazzaneo, M. C., Suryawan, A., Orellana, R. A., Torrazza, R. J. M., El‐Kadi, S. W., Wilson, F. A., Kimball, S. R., Srivastava, N., Nguyen, H. V., Fiorotto, M. L., et al. (2011) · Journal of Nutrition · doi:10.3945/jn.111.147520 · Cited by 74
Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: More than just AKT inhibition
Sun, H. Y., Yu, T., & Li, J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.010 · Cited by 73
FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells
Schuster, S., Penke, M., Gorski, T., Gebhardt, R., Weiß, T. S., Kieß, W., & Garten, A. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.111 · Cited by 77
mTOR, a New Potential Target for Chronic Pain and Opioid-Induced Tolerance and Hyperalgesia
Lutz, B. M., Nia, S., Xiong, M., Tao, Y., & Bekker, A. (2015) · Molecular Pain · doi:10.1186/s12990-015-0030-5 · Cited by 73
Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens
Ng, K., Tabernero, J. M., Hwang, J. J., Bajetta, E., Sharma, S., Prete, S. A. D., Arrowsmith, E. R., Ryan, D. P., Šedová, M., Jin, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0027 · Cited by 75
N-Methyl-N-nitrosourea as a mammary carcinogenic agent
Faustino‐Rocha, A. I., Ferreira, R. M., Oliveira, P. A., Gama, A., & Ginja, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3973-2 · Cited by 78
Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials
Iacovelli, R., Palazzo, A., Mezi, S., Morano, F., Naso, G., & Cortesi, E. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.705019 · Cited by 73
High Expression of GOLPH3 in Esophageal Squamous Cell Carcinoma Correlates with Poor Prognosis
Wang, J., Chen, X.-T., Wen, Z., Zheng, M., Deng, J.-M., Wang, M., Lin, H., Chen, K., Li, J., Yun, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045622 · Cited by 74
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Souteiro, P., & Karavitaki, N. (2019) · Pituitary · doi:10.1007/s11102-019-00987-3 · Cited by 71
mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes
Eid, S., Boutary, S. S., Braysh, K., Sabra, R., Massaad, C., Hamdy, A., Rashid, A., Moodad, S., Block, K. L., Gorin, Y. C., et al. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6562 · Cited by 73
The Mechanism of Action of Biguanides: New Answers to a Complex Question
Magno, L. D., Pastena, F. D., Bordone, R., Coni, S., & Canettieri, G. (2022) · Cancers · doi:10.3390/cancers14133220 · Cited by 81
PI3Kγ Mediates Kaposi's Sarcoma-Associated Herpesvirus vGPCR-Induced Sarcomagenesis
Martı́n, D., Galisteo, R., Molinolo, A., Wetzker, R., Hirsch, E., & Gutkind, J. S. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.005 · Cited by 70
Signals, synapses, and synthesis: how new proteins control plasticity
Zukin, R. S. (2009) · Frontiers in Neural Circuits · doi:10.3389/neuro.04.014.2009 · Cited by 75
Rapamycin encapsulated in dual-responsive micelles for cancer therapy
Chen, Y., Lo, C.-L., Lin, Y., & Hsiue, G.-H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.034 · Cited by 70
Activation by insulin and amino acids of signaling components leading to translation initiation in skeletal muscle of neonatal pigs is developmentally regulated
Suryawan, A., Orellana, R. A., Nguyen, H. V., Jeyapalan, A. S., Fleming, J. R., & Davis, T. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00307.2007 · Cited by 70
mTORC1 impedes osteoclast differentiation via calcineurin and NFATc1
Huynh, H., & Wan, Y. (2018) · Communications Biology · doi:10.1038/s42003-018-0028-4 · Cited by 71
Regulation of Mammalian Target of Rapamycin Activity in PTEN-Inactive Prostate Cancer Cells by IκB Kinase α
Dan, H. C., Adli, M., & Baldwin, A. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1232 · Cited by 70
Tuberous Sclerosis Complex Proteins 1 and 2 Control Serum-Dependent Translation in a TOP-Dependent and -Independent Manner
Bilanges, B., Argonza-Barrett, R., Kolesnichenko, M., Skinner, C., Nair, M., Chen, M., & Stokoe, D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02136-06 · Cited by 68
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
Mateo, J., Olmos, D., Dumez, H., Poondru, S., Samberg, N. L., Barr, S. M., Tornout, J. M. V., Jie, F., Sandhu, S. K., Tan, D. S. W., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.59 · Cited by 68
The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets
Cui, J., Shen, H., & Lim, L. H. K. (2020) · Pharmaceuticals · doi:10.3390/ph13120432 · Cited by 72
Implications of mitogen‐activated protein kinase signaling in glioma
Pandey, V., Bhaskara, V. K., & Babu, P. P. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23687 · Cited by 69
Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy
Chang, Z., Shi, G., JIN, J., Huatao, G., Guo, X., LUO, F., Yu-guo, S., & Jia, X. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1351 · Cited by 68
Cardiomyocyte autophagy and cancer chemotherapy
Li, D. ‘., & Hill, J. A. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.11.007 · Cited by 69
RETRACTED: CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling
Jiang, F., Chen, L., Yang, Y., Wang, X., Wang, R., Li, L., Wen, W., Chang, Y., Chen, C., Tang, J. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1589 · Cited by 68
Retracted
cAMP-Dependent Activation of Mammalian Target of Rapamycin (mTOR) in Thyroid Cells. Implication in Mitogenesis and Activation of CDK4
Blancquaert, S., Wang, L., Paternot, S., Coulonval, K., Dumont, J. E., Harris, T. E., & Roger, P. P. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0087 · Cited by 71
Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
Fowler, A. J., Hebron, M. L., Missner, A. A., Wang, R., Gao, X., Kurd-Misto, B. T., Liu, X., & Moussa, C. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0266-z · Cited by 70
Smooth Muscle–like Cells in Pulmonary Lymphangioleiomyomatosis
Krymskaya, V. P. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200705-061vs · Cited by 69
Intravesical delivery of rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel
Yoon, H. Y., Chang, I. H., Goo, Y. T., Kim, C. H., Kang, T. H., Kim, S.-Y., Lee, S. J., Song, S. H., Whang, Y. M., & Choi, Y. W. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s216432 · Cited by 67
AP-1 Regulates Cyclin D1 and c-MYC Transcription in an AKT-Dependent Manner in Response to mTOR Inhibition: Role of AIP4/Itch-Mediated JUNB Degradation
Vartanian, R., Masri, J., Martin, J., Cloninger, C., Holmes, B., Artinian, N., Funk, A., Ruegg, T., & Gera, J. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0105 · Cited by 68
Inhibitors of mTOR
Klümpen, H., Beijnen, J. H., Gurney, H., & Schellens, J. H. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0196 · Cited by 69
Targeting the mTOR-DEPTOR Pathway by CRL E3 Ubiquitin Ligases: Therapeutic Application
Zhao, Y., & Sun, Y. (2012) · Neoplasia · doi:10.1593/neo.12532 · Cited by 68
Hypoxia-Inducible Factor 1 Regulation through Cross Talk between mTOR and MT1-MMP
Sakamoto, T., Weng, J. S., Hara, T., Yoshino, S., Kozuka‐Hata, H., Oyama, M., & Seiki, M. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01169-13 · Cited by 64
Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis
Laudański, P., Szamatowicz, J., Kowalczuk, O., Kuźmicki, M., Grabowicz, M., & Chyczewski, L. (2009) · Human Reproduction · doi:10.1093/humrep/dep175 · Cited by 65
An Evolving Role for DEPTOR in Tumor Development and Progression
Wang, Z. P., Zhong, J., Inuzuka, H., Gao, D., Shaik, S., Sarkar, F. H., & Wei, W. (2012) · Neoplasia · doi:10.1593/neo.12542 · Cited by 66
Vascular Endothelial Growth Factor-C Protects Prostate Cancer Cells from Oxidative Stress by the Activation of Mammalian Target of Rapamycin Complex-2 and AKT-1
Muders, M. H., Zhang, H., Wang, E., Tindall, D. J., & Datta, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0552 · Cited by 63
Polyphenolics from mango (Mangifera indica L.) suppress breast cancer ductal carcinoma in situ proliferation through activation of AMPK pathway and suppression of mTOR in athymic nude mice
Nemec, M. J., Kim, H., Marciante, A. B., Barnes, R. C., Hendrick, E. D., Bisson, W. H., Talcott, S. T., & Mertens‐Talcott, S. U. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.11.005 · Cited by 65
Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling
Wang, K., Huang, W., Sang, X., Wu, X., Shan, Q., Tang, D.-X., Xu, X., & Cao, G. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153191 · Cited by 65
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
Hurvitz, S. A., Kalous, O., Conklin, D. F., Desai, A. J., Dering, J., Anderson, L. A., O’Brien, N. A., Kolarova, T. R., Finn, R. S., Linnartz, R., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3282-x · Cited by 69
Significance of filamin A in mTORC2 function in glioblastoma
Chantaravisoot, N., Wongkongkathep, P., Loo, J. A., Mischel, P. S., & Tamanoi, F. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0396-z · Cited by 64
Recent advances in the treatment of metastatic renal cell carcinoma
Abe, H., & Kamai, T. (2013) · International Journal of Urology · doi:10.1111/iju.12187 · Cited by 64
GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR‐YB1 pathway in vitro
Zhang, X., Ding, Z., Mo, J., Sang, B., Shi, Q., Hu, J., Xie, S. P., Zhan, W., Lu, D., Yang, M., et al. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22197 · Cited by 65
New Potential Pharmacological Functions of Chinese Herbal Medicines via Regulation of Autophagy
Law, B. Y. K., Mok, S. W. F., Wu, A., Lam, C. W. K., Yu, M., & Wong, V. K. W. (2016) · Molecules · doi:10.3390/molecules21030359 · Cited by 65
mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy
Seo, S. U., Woo, S. M., Lee, H., Kim, S. H., Min, K., & Kwon, T. K. (2018) · Oncogene · doi:10.1038/s41388-018-0345-6 · Cited by 65
Mitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformation
Velásquez, C., Cheng, E., Shuda, M., Lee-Oesterreich, P. J., von Strandmann, L. P., Gritsenko, M. A., Jacobs, J., Moore, P. S., & Chang, Y. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607768113 · Cited by 66
Chapter 11 Monitoring Mammalian Target of Rapamycin (mTOR) Activity
Ikenoue, T., Hong, S., & Inoki, K. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(08)03611-2 · Cited by 62
Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma
Hirashima, K., Baba, Y., Watanabe, M., Karashima, R.-I., Sato, N., Imamura, Y., Hiyoshi, Y., Nagai, Y., Hayashi, N., Iyama, K.-I., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1040-1 · Cited by 61
Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice #
Lang, S. A., Moser, C., Fichnter-Feigl, S., Schachtschneider, P., Hellerbrand, C., Schmitz, V., Schlitt, H. J., Geissler, E. K., & Stoeltzing, O. (2008) · Hepatology · doi:10.1002/hep.22685 · Cited by 62
Peripheral axon regrowth: New molecular approaches
Christie, K. J., & Zochodne, D. W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.02.059 · Cited by 65
Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway
Feng, T., Zheng, L., Liu, F., Xu, X., Mao, S., Wang, X., Liu, J., Lu, Y., Zhao, W., Yu, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11126 · Cited by 62
TUFT1 interacts with RABGAP1 and regulates mTORC1 signaling
Kawasaki, N., Isogaya, K., Dan, S., Yamori, T., Takano, H., Yao, R., Morishita, Y., Taguchi, L., Morikawa, M., Heldin, C., et al. (2018) · Cell Discovery · doi:10.1038/s41421-017-0001-2 · Cited by 67
Regulation of spindle and kinetochore‐associated protein 1 by antitumor miR‐10a‐5p in renal cell carcinoma
Arai, T., Okato, A., Kojima, S., Idichi, T., Koshizuka, K., Kurozumi, A., Kato, M., Yamazaki, K., Ishida, Y., Naya, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13331 · Cited by 61
CircRNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145
Yang, H., Zhao, M., Zhao, L., Li, P., Duan, Y., & Li, G. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00503-x · Cited by 61
The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas
Lee, D., Do, I., Choi, K., Sung, C. O., Jang, K., Choi, D.-W., Heo, J. S., Choi, S. H., Kim, J., Park, J. Y., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.133 · Cited by 62
De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
Tarrado‐Castellarnau, M., de Atauri, P., Tarragó‐Celada, J., Perarnau, J., Yuneva, M. O., Thomson, T. M., & Cascante, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167321 · Cited by 60
DEPTOR regulates osteogenic differentiation via inhibiting MEG3-mediated activation of BMP4 signaling and is involved in osteoporosis
Chen, S., Jia, L., Zhang, S., Zheng, Y., & Zhou, Y. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0935-9 · Cited by 60
Thymic Stromal-Derived Lymphopoietin Induces Proliferation of Pre-B Leukemia and Antagonizes mTOR Inhibitors, Suggesting a Role for Interleukin-7Rα Signaling
Brown, V. I., Hulitt, J., Fish, J. D., Sheen, C., Bruno, M., Xu, Q., Carroll, M. P., Fang, J., Teachey, D. T., & Grupp, S. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4704 · Cited by 60
mTOR is required for asymmetric division through small GTPases in mouse oocytes
Lee, S., Sun, S., Choi, H., Uhm, S. J., & Kim, N. (2012) · Molecular Reproduction and Development · doi:10.1002/mrd.22035 · Cited by 60
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex
Γκουντάκος, Α., Pilotto, S., Mafficini, A., Vicentini, C., Simbolo, M., Milella, M., Tortora, G., Scarpa, A., Bria, E., & Corbo, V. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy086 · Cited by 60
Candidate mechanisms accounting for effects of physical activity on breast carcinogenesis
Thompson, H. J., Jiang, W., & Zhu, Z. (2009) · IUBMB Life · doi:10.1002/iub.233 · Cited by 59
“Much remains to be done in understanding how PA regulates mTOR in mammary gland and mammary carcinomas, and a logical next step is investigation of effects on TORC1 and TORC2.”
BackgroundInfluential
Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells
Zito, C. R., Jilaveanu, L. B., Anagnostou, V., Rimm, D. L., Bepler, G., Maira, S.-M., Hackl, W., Camp, R. L., Kluger, H. M., & Chao, H. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031331 · Cited by 60

Authors: Sabatini, D. M.
Affiliations: Whitehead Institute for Biomedical Research (US)
Corresponding author: Sabatini, David M.
ORCID: Sabatini, David M.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2006-08-17
Volume: 6
Issue: 9
Pages: 729-734
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc1974
OpenAlex: W2060157525
Cited by: 1,322
References: 94
Citations by year: 2026: 10 · 2025: 21 · 2024: 31 · 2023: 46 · 2022: 38 · 2021: 33 · 2020: 51 · 2019: 52 · 2018: 60 · 2017: 62 · 2016: 79 · 2015: 87 · 2014: 80 · 2013: 102 · 2012: 98
FWCI: 6.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: Pew Charitable Trusts
Rita Allen Foundation
Allen Foundation
National Trust for Historic Preservation
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: mTOR, mTOR inhibitors, mTORC1, mTORC2, cancer therapy, mechanism of action, rapamycin, kinase signaling, targeted cancer drugs
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Protein Kinases, Signal Transduction, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

mTOR and cancer: insights into a complex relationship

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks